Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
暂无分享,去创建一个
A. Stopeck | David Henry | M. Danese | Y. Qian | M. Rader | K. Chung | R. Dansey | M. Halperin | Z. Cong